Current management of severe ulcerative colitis

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 2, 2007, Pages 92-101

  Caprilli, Renzo ^a   Viscido, Angelo ^a   Latella, Giovanni ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN A; GANCICLOVIR; GLUCOCORTICOID; HEPARIN; HUMAN ALBUMIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; STEROID; VISILIZUMAB; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL RADIOGRAPHY; ALBUMIN BLOOD LEVEL; ALLERGIC REACTION; ARTHRALGIA; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COLON PERFORATION; COLON RESECTION; COLON ULCER; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EARLY INTERVENTION; ELECTROLYTE DISTURBANCE; EMERGENCY SURGERY; FATIGUE; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; ILEOSTOMY; INFECTION; INTESTINE DISTENSION; INTRAVENOUS FEEDING; KIDNEY FAILURE; LABORATORY TEST; LEUKAPHERESIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; METABOLIC ACIDOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; NUTRITIONAL SUPPORT; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; SCORING SYSTEM; SIDE EFFECT; THROMBOEMBOLISM; TOXIC MEGACOLON; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS LOAD; HOSPITALIZATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847708703     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0687     Document Type: Review

References (70)

1. Sonnenberg A and Koch TR (1989) Period and generation effect on mortality from idiopathic inflammatory bowel disease. Dig Dis Sci 34: 1720-1729
2. Carter MJ et al. (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (Suppl V): V1-V16
3. Winther KV et al. (2003) Survival and cause-specific mortality in ulcerative colitis: Follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125: 1576-1582
4. Card T et al. (2003) Mortality in Inflammatory Bowel Disease: A population-based cohort study. Gastroenterology 125: 1583-1590
5. Loftus EV Jr (2003) Mortality in inflammatory bowel disease: Peril and promise. Gastroenterology 125: 1881-1883
6. Hardy TL and Bulmer E (1933) Ulcerative colitis: Survey of 95 cases. Br Med J 2: 812-815
7. Rice-Oxley JM and Truelove SC (1950) Ulcerative colitis: Course and prognosis. Lancet 1: 663-666
8. Truelove SC and Witts LJ (1955) Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 2: 1041-1048
9. Truelove SC and Jewell DP (1974) Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1: 1067-1070
10. Lichtiger S et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841-1845
11. D'Haens G et al. (2001) Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120: 1323-1329
12. Van Assche G et al. (2003) Randomized double-blind comparison of 4 mg/Kg versus 2 mg/Kg intravenous Cyclosporin in severe ulcerative colitis. Gastroenterology 125: 1025-1031
13. Campbell S et al. (2005) Cyclosporine use in acute ulcerative colitis: A long term experience. Eur J Gastroenterol Hepatol 17: 79-84
14. Probert CSJ et al. (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomized controlled trial. Gut 52: 998-1002
15. Rutgeerts P et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476
16. Jarnerot G et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 128: 1805-1811
17. Shibolet O et al. (2005) Cyclosporine-A for induction of remission in severe ulcerative colitis. The Cochrane Database of Systematic Reviews Issue 1, Art. No CD004277
18. Silverberg MS et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease. Can J Gastroenterol 19 (Suppl A): 5-36
19. Jalan KN et al. (1969) An experience of ulcerative colitis. Gastroenterology 57: 68-82
20. Caprilli R et al. (2000) Multiple organ dysfunction in ulcerative colitis. Am J Gastroenterol 95: 1258-1262
21. Lennard-Jones JE et al. (1975) Assessment of severity in colitis: A preliminary study. Gut 16: 579-584
22. Caprilli R et al. (1976) Blood pH: A test for assessment of severity on proctocolitis. Gut 17: 763-769
23. Caprilli R et al. (1978) Salt loosing diarrhoea in idiopathic proctocolitis. Scand J Gastroenterol 13: 331-335
24. Caprilli R et al. (1980) Risk factors in toxic megacolon. Dig Dis Sci 25: 817-822
25. Travis SPL et al. (1996) Predicting outcome in severe ulcerative colitis. Gut 38: 905-910
26. Ahmad T et al. (2006) Genetics of inflammatory bowel disease: The role of HLA complex. World J Gastroenterol 12: 3628-3635
27. Ho GT et al. (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: Discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15: 797-805
28. Caprilli R et al. (1987) Early recognition of toxic megacolon. J Clin Gastroenterol 9:160-164
29. Chew CN (1991) Small bowel gas in severe ulcerative colitis. Gut 32: 1535-1537
30. Caprilli R and Onori L (1992) Pathogenesis of gastrointestinal distension in severe ulcerative colitis: A hypothesis. Gastroenterol Int 5: 268-272
31. Jones JH and Chapman M (1969) Definition of megacolon in colitis. Gut 10: 562-564
32. Latella G et al. (2002) GI distension in severe ulcerative colitis. Am J Gastroenterol 97: 1169-1175
33. Mourelle M et al. (1995) Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 109: 1497-1502
34. Onori L et al. (2005) Role of nitric oxide in the impairment of circular muscle contractility of distended, uninflamed mid-colon in TNBS-induced acute distal colitis in rats. World J Gastroenterol 11: 5677-5684
35. Carbonnel F et al. (1994) Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 39: 1550-1557
36. Carbonnel F et al. (2000) Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 14: 273-279
37. Buckell NA et al. (1980) Depth of ulceration in acute colitis. Correlation with outcome and clinical and radiological features. Gastroenterology 79: 19-25
38. Naber AHJ and de Jong DJ (2003) Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 61: 105-110
39. Seo M (1992) An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87: 971-976
40. Walmsley RS et al. (1998) A simple clinical colitis activity index. Gut 43: 29-32
41. Su C et al. (2002) Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 97: 2577-2584
42. Lindgren SC (1998) Early predictors of glucocorticoid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10: 831-835
43. Higgins PDR et al. (2005) Is encloscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 100: 355-361
44. Truelove SC et al. (1978) Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2: 1086-1088
45. Meyers S and Janowitz HD (1985) Corticosteroid therapy of ulcerative colitis. Gastroenterology 89: 1189-1191
46. Powell-Tuck J et al. (1977) A controlled trial of corticotrophin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 12: 971-975
47. Meyers S et al. (1983) Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 85: 351-357
48. Meyers S et al. (1987) Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 9: 50-54
49. Lees C et al. (2006) Infliximab is effective as rescue therapy for acute severe ulcerative colitis. The initial Edinburgh experience. Gastroenterology 130 (Suppl 2): A-656
50. Walsh A et al. (2006) Acute severe ulcerative colitis: A study of predictors of outcome and efficacy for Cyclosporin and Infliximab. Gastroenterology 130 (Suppl 2): A-84
51. Regueiro M et al. (2006) Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 40: 476-481
52. Lichtenstein GR et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630
53. Baumgart DC et al. (2005) The phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids. Gut 54 (Suppl VII): A57
54. Sawada K et al. (2005) Leukocytapheresis for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 10: 1-7
55. McIntyre DB et al. (1986) Controlled trial of bowel rest in the treatment of severe colitis. Gut 27: 481-485
56. Chapman RW et al. (1986) Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Gut 27: 1210-1212
57. Greenstein AJ et al. (1985) Outcome of toxic dilation in ulcerative colitis and Crohn's colitis. J Clin Gastroenterol 7: 137-143
58. Gan SI and Beck PL (2003) A new look at toxic megacolon: An update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 98: 2363-2371
59. Imbriaco M et al. (2001) Toxic megacolon. Role of CT in evaluation and detection of complications. Clin Imaging 25: 349-354
60. Present DH et al. (1988) Medical decompression of toxic megacolon by "rolling". J Clin Gastroenterol 10: 485-490
61. Panos MS et al. (1993) Toxic megacolon: The knee-elbow position relieves bowel distension. Gut 34: 1726-1727
62. Buchman AL (2001) Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 33: 337-339
63. Riedel L (1989) Endoscopic decompression in toxic megacolon. Surg Endosc 3: 51
64. Cottone M et al. (2001) Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 96: 773-775
65. Kambham N et al. (2004) Cytomegalovirus infection in steroid-refractory ulcerative colitis: A case-control study. Am J Surg Pathol 28: 365-373
66. Zer M et al. (1972) Pitfalls in the surgical management of fulminating ulcerative colitis. Dis Colon Rectum 15: 280-287
67. Softley A et al. (1988) Perforation of the intestine in IBD. An OMGE survey. Scand J Gastroenterol 23 (Suppl 144): 24-26
68. Robert JH et al. (1990) Management of severe hemorrhage in ulcerative colitis. Am J Surg 159: 550-555
69. Jewell DP et al. (1991) Working Team Report. Indications and timing of surgery for severe ulcerative colitis. Gastroenterol Int 4: 161-164
70. Cohen JL (2005) Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 48: 1997-2009